Fundraising FoxAMR Action Fund — 2023 Investments
4 investments dated 2023 · listed companies and verified rows first · show all
Pattern develops rapid antibiotic susceptibility and infection diagnostics using single-cell microbiology, which reads the metabolic patterns of individual bacterial cells to deliver ID/AST results in hours without culture steps.
BiotechHealthtechMedical DevicesAustin, US
Nick Arab(Founder & CTO)Ross Johnson(Co-founder & Chief Engineer)inCarey-Ann Burnham(Chief Executive Officer)inTravis Davies(SVP, Operations)inKyle Fieleke(SVP, Corporate Development & Finance)inDavid Bussian(SVP, Clinical, Regulatory & Assay Development)in
Co-investorsIllumina VenturesIllumina Innovation
Aphage develops AI and sensor technologies to identify, track, and classify physical threats across borders, infrastructure, and transportation networks for government and security organizations.
AI & Machine LearningBiotechDefense TechGovTechGaithersburg, IL
Gregory L. Merril(Executive Officer, Director, Promoter)Carl R. Merril(Executive Officer, Director)in
BoardJonathan Leff(Director)inEvan Loh(Director)Jana Jensen(Director)Raymond L. Martz(Director)
Board seatMartin Heidecker· per SEC Form D
Co-investorsHackensack Meridian Health Bear's DenMaryland TEDCOTEDCODeerfield Management CompanySofinnova Ventures
Vedanta Biosciences is a clinical-stage biotech developing Live Biotherapeutic Products (LBP) based on defined consortia of bacteria to treat serious gastrointestinal diseases, with an initial focus on preventing recurrent Clostridium difficile infection.
BiotechHealthtechCambridge, US
Bernat Olle(Executive Officer, Director)inDaniel Couto(Executive Officer)inMark Mullikin(Executive Officer)inJeffrey Silber(Executive Officer)inChristopher Viehbacher(Director)
BoardJohn LaMattina(Director)in
Board seatMartin Heidecker· per SEC Form D
Co-investorsColorcon VenturesK2 HealthVenturesSalica InvestmentsSeventure PartnersBNP ParibasBNP Paribas Asset Management Europe+2 more
BioVersys is a clinical-stage biotech company focused on developing antimicrobial therapies to address unmet medical needs in infectious diseases, including tuberculosis and hospital-acquired infections.
BiotechDeep TechHealthtechMedical DevicesBasel, CH
Dr. Marc Gitzinger(Chief Executive Officer & Founder)
Co-investorsStartAngels Network
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.